---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-129981"
form_type: "8-K"
ticker: "ARMP"
cik: "0000921114"
company_name: "Armata Pharmaceuticals, Inc."
filed_at: "2024-12-19T23:59:59+00:00"
generated_at: "2026-05-29T01:53:54.440504+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Armata Pharmaceuticals Announces Phase 2 Tailwind Study Results for Inhaled AP-PA02 in NCFB Subjects

## Summary
- Post-hoc analysis showed statistically significant reduction of P.a. CFUs at day 17 (P=0.05) and day 24 (P=0.015).
- Approximately one-third of AP-PA02 monotherapy subjects achieved at least a 2-log CFU reduction versus none on placebo.
- Inhaled AP-PA02 was well-tolerated with mild, self-limiting adverse events; one possibly related serious adverse event reported.
- AP-PA02 is a novel multi-phage therapeutic for chronic Pseudomonas aeruginosa infections in non-cystic fibrosis bronchiectasis.
- Results suggest AP-PA02 monotherapy may be as effective as combination with anti-pseudomonal antibiotics in reducing lung P.a. burden.

## SEC filing metadata
- accession: 0001104659-24-129981
- form_type: 8-K
- ticker: ARMP
- cik: 0000921114
- company_name: Armata Pharmaceuticals, Inc.
- filed_at: 2024-12-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921114/000110465924129981/0001104659-24-129981-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921114/000110465924129981/tm2431487d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-129981
- JSON: https://secwatch.observer/filing/0001104659-24-129981.json
- Plain text: https://secwatch.observer/filing/0001104659-24-129981.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.